{
    "organizations": [],
    "uuid": "134d6551232ccc5ad0cc2b5f18142b054e53bf4c",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/pfizer-study/pfizers-rare-disease-drug-succeeds-in-late-stage-study-idUSL3N1RB5YE",
    "ord_in_thread": 0,
    "title": "Pfizer's rare disease drug succeeds in late-stage study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 29 (Reuters) - Pfizer Inc said on Thursday its drug for a rare and fatal disease associated with progressive heart failure met the main goal in a late-stage study.\nThe company said the drug, tafamidis, showed statistically significant reduction in deaths and frequency of cardiovascular-related hospitalizations compared to a placebo at 30 months. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Shounak Dasgupta)\n ",
    "published": "2018-03-30T01:06:00.000+03:00",
    "crawled": "2018-03-30T12:47:12.002+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "pfizer",
        "inc",
        "said",
        "thursday",
        "drug",
        "rare",
        "fatal",
        "disease",
        "associated",
        "progressive",
        "heart",
        "failure",
        "met",
        "main",
        "goal",
        "study",
        "company",
        "said",
        "drug",
        "tafamidis",
        "showed",
        "statistically",
        "significant",
        "reduction",
        "death",
        "frequency",
        "hospitalization",
        "compared",
        "placebo",
        "month",
        "reporting",
        "akankshita",
        "mukhopadhyay",
        "bengaluru",
        "editing",
        "shounak",
        "dasgupta"
    ]
}